In the BioHarmony Drug Report Database
Amisulpride
Barhemsys, Solian (amisulpride) is a small molecule pharmaceutical. Amisulpride was first approved as Barhemsys on 2020-02-26. The pharmaceutical is active against D(2) dopamine receptor and D(3) dopamine receptor. Barhemsys, solian’s patent is valid until 2031-03-10 (FDA).
Trade Name
|
Solian |
|---|---|
Common Name
|
amisulpride |
ChEMBL ID
|
CHEMBL243712 |
Indication
|
|
Drug Class
|
Sulpride derivatives |
Image (chem structure or protein)